IQVIA Holdings Inc. IQV
- Market cap
- $45.3B
- P/E
- 33.3×
Follow IQV
IQVIA Holdings Inc. (IQV) EV/Sales
As of 25 September 2026, IQVIA Holdings Inc. (IQV) trades at a EV/Sales of 3.5×. Over the past ten years it has ranged from 1.5× (February 2016) to 4.8× (December 2021); the current reading is higher than 58% of that period. That is below the Diagnostics & Research industry median of 5.7× and in line with the Healthcare sector median of 3.6×.
EV/Sales, daily
Annual
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.2× | 3.47% |
| FY2024 | 3.1× | (14.78%) |
| FY2023 | 3.6× | 5.54% |
| FY2022 | 3.4× | (26.01%) |
| FY2021 | 4.7× | 17.87% |
| FY2020 | 4.0× | 7.20% |
| FY2019 | 3.7× | 13.83% |
| FY2018 | 3.2× | 1.57% |
| FY2017 | 3.2× | 24.70% |
| FY2016 | 2.6× | 47.69% |
Quarterly
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.7× | 6.16% |
| Mar 2026 | 2.6× | (20.46%) |
| Dec 2025 | 3.2× | 12.61% |
| Sep 2025 | 2.8× | 10.79% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DGX Quest Diagnostics Incorporated compare | 2.7× |
| IQV IQVIA Holdings Inc. | 3.5× |
| A Agilent Technologies, Inc. compare | 6.9× |
| MTD Mettler-Toledo International, Inc. compare | 7.9× |
| IDXX IDEXX Laboratories, Inc. compare | 9.1× |
| ILMN Illumina, Inc. compare | 9.3× |
| WAT Waters Corporation compare | 10.1× |
| GH Guardant Health, Inc. compare | 20.3× |
| NTRA Natera, Inc. compare | 21.6× |
| Diagnostics & Research industry median | 5.7× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on IQV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement